I have been trading both AEZS and KERX for over a year now. The reason KERX is trading at a higher price than AEZS because more institutions were trading KERX. The reason more institution were trading KERX is because it is an American company. More marketing research had done on American biotech companies than Canadian biotech companies. So, it is a matter of exposure to the marketers. If Perifosine is approved, AEZS will be equally attractive as KERX. Obama's Medicaid and Medicare change has negatively affected DNDN's sales of PROVENGE. It will also negatively affect KERX's sale of Perifosine in the US market if it gets approved by the FDA. So my point is the stock price of AEZS will be higher than KERX if Perifosine is approved FDA and Obama is still the president.